Arrivent BioPharma, Inc. (AVBP)
13.34
-0.02
(-0.11%)
USD |
NASDAQ |
Nov 03, 13:28
Arrivent BioPharma Net Income (Quarterly) : -49.89M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -49.89M |
| March 31, 2026 | -43.32M |
| December 31, 2025 | -35.54M |
| September 30, 2025 | -34.98M |
| June 30, 2025 | -31.40M |
| March 31, 2025 | -64.39M |
| December 31, 2024 | -20.63M |
| September 30, 2024 | -20.56M |
| Date | Value |
|---|---|
| June 30, 2024 | -21.87M |
| March 31, 2024 | -17.42M |
| December 31, 2023 | -21.19M |
| September 30, 2023 | -14.40M |
| June 30, 2023 | -21.57M |
| March 31, 2023 | -12.17M |
| December 31, 2022 | -10.44M |
| September 30, 2022 | -11.77M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Xencor, Inc. | -21.73M |
| NovaBridge Biosciences | -73.18M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 49.89M |
| EPS Diluted (Quarterly) | -1.048 |
| Enterprise Value | 272.30M |
| Earnings Yield | -27.60% |
| Normalized Earnings Yield | -27.60 |